ArticleEBioMedicine2020

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.

Xinan Sheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.